[2] More frequent dosing increases adverse effect risk without therapeutic benefit
The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) reported 14.9% mean weight loss with FDA-approved 2.4mg semaglutide over 68 weeks
Support may come from various sources, including healthcare practitioners offering guidance on optimizing lifestyle changes or possibly from a dedicated coaching program that pairs science with professional advice and encouragement
Other drugs, like some types of antidepressants or bladder relaxants, may also influence how often you urinate
Implementing practical strategies can significantly reduce the risk of storage errors with tirzepatide and other temperature-sensitive diabetes medications
Change in waist circumference : The mean change in waist circumference was 18.4 cm with tirzepatide (95% CI, 19.6 to 17.2) and 13.0 cm with semaglutide (95% CI, 14.3 to 11.7)